细胞因子释放综合征：当前展望

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2019-10-01 DOI:10.2147/ITT.S202015

H. Murthy, M. Iqbal, J. Chavez, M. Kharfan-Dabaja

{"title":"细胞因子释放综合征：当前展望","authors":"H. Murthy, M. Iqbal, J. Chavez, M. Kharfan-Dabaja","doi":"10.2147/ITT.S202015","DOIUrl":null,"url":null,"abstract":"Abstract Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"8 1","pages":"43 - 52"},"PeriodicalIF":6.2000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ITT.S202015","citationCount":"93","resultStr":"{\"title\":\"Cytokine Release Syndrome: Current Perspectives\",\"authors\":\"H. Murthy, M. Iqbal, J. Chavez, M. Kharfan-Dabaja\",\"doi\":\"10.2147/ITT.S202015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.\",\"PeriodicalId\":30986,\"journal\":{\"name\":\"ImmunoTargets and Therapy\",\"volume\":\"8 1\",\"pages\":\"43 - 52\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2019-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/ITT.S202015\",\"citationCount\":\"93\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ImmunoTargets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ITT.S202015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S202015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 93

摘要

摘要嵌合抗原受体T细胞（CART）治疗是治疗癌症的一种新的和准转移的方法。最近的临床成功扩大了CD19 CART细胞治疗复发/难治性B细胞NHL的适用性，即tisagenlucel和axcabtagene cilloucel。Tisangeleclacel也被批准用于25岁以下的复发性和/或难治性B-ALL。CART治疗与独特且可能危及生命的毒性有关，尤其是细胞因子释放综合征（CRS）。更好地了解CRS的发病机制对于确保正确的管理至关重要。在这篇综述中，讨论了CRS的定义、概况、风险因素和分级系统。最后，总结了目前和新的CRS研究方法和治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cytokine Release Syndrome: Current Perspectives

Abstract Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.